About the Author
Scott Kjelson, PharmD, is a manager of pharmacy innovation and emerging therapies at Baptist Health South Florida.
Pharmacy Practice in Focus: Health Systems
The breakthrough is not only in cell and gene therapies but also in whether health care can translate them into practice.
Scott Kjelson, PharmD, is a manager of pharmacy innovation and emerging therapies at Baptist Health South Florida.
The author has nothing to disclose.
Rare diseases have never been a small problem; they have only been treated as one. Increasingly, what health care is learning from them reaches far beyond rare disease itself. Despite the label rare, these conditions collectively affect an estimated 25 million to 30 million Americans and more than 300 million people worldwide at the time of writing this article.1,2 More than 10,000 rare diseases have been identified, and approximately 80% are genetic in origin.3,4 For patients and families, expertise can be scattered across specialties and institutions. Finding an answer may take years of appointments, referrals, testing, and uncertainty—the diagnostic odyssey. Delays can mean inappropriate treatment, disease progression, added costs, and physical and emotional strain.5
Sickle cell disease puts both the promise and the difficulty of advanced therapies in human terms. Severe vaso-occlusive pain can begin in childhood and return throughout life, bringing emergency visits, hospitalizations, and years of treatment. Patients have also described stigma, trouble finding appropriate care, and having their pain dismissed.6
In December 2023, the FDA approved the first 2 cell-based gene therapies for sickle cell disease. Exagamglogene autotemcel (exa-cel; Casgevy; Vertex Pharmaceuticals, CRISPR Therapeutics) became the first FDA-approved therapy to use genome editing with clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9.7 One Florida patient described the treatment candidly: “My hair fell out…I had mouth sores, I was throwing up…. Mentally, it was hard being in the hospital for so long.”8 The process included stem cell collection and modification, conditioning chemotherapy, hospitalization, and recovery. Afterward, his description of life was remarkably simple: “I have no pain…it’s how normal people feel.”8
The breakthrough is not only the therapy itself; it is whether health care can translate it into a life changed.
Rare and genetic diseases have been a proving ground for some of today’s most advanced therapies, but they were never the destination. In the second quarter of 2026, the American Society of Gene and Cell Therapy and Citeline reported 4487 gene, cell, and RNA therapies in development worldwide, from preclinical research through preregistration. The pipeline now reaches beyond rare disease into cancer, autoimmune disorders, and increasingly common conditions.9
Imagine telling a cardiologist, neurologist, endocrinologist, or rheumatologist 5 years ago that technologies refined through rare and genetic disease might soon influence how we approach heart disease, Parkinson disease, autoimmune disorders, obesity, or other common conditions. The conversation might have sounded more like science fiction than strategic planning. Today, it is becoming both.
Money is following the science. The Alliance for Regenerative Medicine reported approximately $4.6 billion in global cell and gene therapy financing in the second quarter of 2026, after approximately $4.8 billion in the first. Work continues across gene editing, scalable platforms, manufacturing, and automation.10-13
For health care, this is bigger than any one specialty. Questions once concentrated in rare disease and oncology may soon be familiar in neurology, cardiology, endocrinology, rheumatology, and elsewhere: Who delivers these therapies? Where does care occur? How is treatment financed? How are outcomes followed? And how does expertise move across the continuum? Rare disease may have helped open the door; what comes through it could reshape medicine.
For generations, medicine has largely focused on slowing disease, managing symptoms, and delaying progression. Advanced therapies raise a different possibility: intervening directly in the biology responsible for disease.
The tools differ. Cell therapies can replace damaged cells or engineer immune cells to recognize disease. Gene therapies can introduce or modify genetic material. RNA-based approaches can change how disease-related proteins are produced, and gene editing can make targeted changes to DNA. Each works closer to the biology driving the disease.
In 2025, investigators treated an infant with a severe, ultrarare metabolic disorder using a personalized base-editing therapy designed for his specific disease-causing variant and developed within months.14 It was 1 patient, and long-term follow-up remains essential. But consider what occurred: A genetic therapy was designed around the biology of a single child.
The treatment process may change, too. Today’s chimeric antigen receptor (CAR) T-cell therapy can require collecting a patient’s cells, engineering them outside the body, preparing the patient with chemotherapy, and returning the modified cells. In 2026, an early phase 1 study generated CAR T cells inside the patient without cell collection, external manufacturing, or lymphodepleting chemotherapy.15 Only 5 patients were treated, but the idea still matters. An in vivo approach could eventually remove entire steps from one of today’s most complex treatment pathways.
These therapies are moving to larger populations. In 2026, early results from the phase 1b Heart-2 trial (NCT06164730), evaluating VERVE-102, an investigational in vivo base-editing therapy targeting PCSK9, demonstrated substantial reductions in PCSK9 and low-density lipoprotein cholesterol after a single infusion in patients with heterozygous familial hypercholesterolemia or premature coronary artery disease.16
These are early examples. Long-term safety, durability, and their eventual place in medicine are still being worked out. Still, the shift is hard to miss. Medicine is beginning to change what it means to live with disease, and the structures surrounding medicine will have to change with it.
Transformative medicine rarely moves neatly from discovery to acceptance. In 2018, the announcement that CRISPR had been used to edit human embryos, resulting in the birth of twin girls, triggered international condemnation and debate over human genome editing.17 The case involved heritable germline editing, which is fundamentally different from editing somatic cells to treat disease. The World Health Organization later established a multidisciplinary expert committee and issued recommendations for responsible governance.18 Five years later, exa-cel reached patients through clinical trials, regulatory review, and defined therapeutic use.7
There is a broader lesson in that progression. Breakthrough science needs evidence, oversight, clinician and patient confidence, workable manufacturing and payment models, and organizations that can deliver it responsibly. Medicine can find the answer before health care is ready to deliver it. When any one of those elements falls behind, innovation risks outpacing implementation.
Rare disease exposes another weakness: Expertise can exist without being easy to reach. A 2026 review described patients encountering “disconnected islands of knowledge.”19 In one expert-center study, patients saw an average of 6 physicians before reaching specialized expertise, and referral took an average of 4 years. Once they arrived, targeted evaluation led to a correct diagnosis in an average of 55 days.20
Organizations should not have to solve the same challenges independently. For patients, fragmentation is not an organizational abstraction. It can determine how many doors they must knock on before someone knows which one to open.
A therapy can transform care and still be extraordinarily difficult to finance. Exa-cel entered the market at a list price of $2.2 million per patient and lovotibeglogene autotemcel (Lyfgenia; Genetix Biotherapeutics) at $3.1 million, excluding the broader costs of treatment and follow-up.21 Even a small number of patients can create significant financial exposure when reimbursement is delayed or incomplete.
Public payment is already adapting. Through the Cell and Gene Therapy Access Model, the Centers for Medicare & Medicaid Services negotiates outcomes-based agreements with manufacturers on behalf of participating Medicaid programs, initially for sickle cell disease. The model includes 32 states, the District of Columbia, and Puerto Rico, representing approximately 84% of Medicaid beneficiaries living with sickle cell disease. Participating states can receive additional rebates when therapies fail to achieve specified outcomes.21
Site of care adds another complication. Medicare pays differently for inpatient and outpatient treatment.22,23 The 340B Drug Pricing Program applies to covered outpatient drugs, not inpatient drugs.24 The Health Resources and Services Administration reported approximately $100 billion in 340B covered-entity drug purchases in 2025 and has recognized the continued movement of care from inpatient to outpatient settings.25 If advanced therapies move toward ambulatory administration, their relationship with 340B, Medicare reimbursement, and manufacturer policies could materially affect access and service-line economics.
There is a deeper mismatch. Traditional payment is built largely around products and services delivered today, whereas the value of a potentially durable therapy may unfold over years. Outcomes-based agreements try to bridge that gap by tying portions of payment to defined clinical results.21 That makes longitudinal follow-up, real-world evidence, patient tracking, and financial reconciliation part of the economic model. Clinical readiness without financial readiness is not readiness at all.
Having a therapy available does not mean that a health system is ready to deliver it. The right specialists, logistics, data, financing, and long-term follow-up may all need to be in place before a patient ever arrives for treatment. Health care has spent decades building models for treating disease over time. It now has to prepare for interventions that may fundamentally alter the course of disease. Sometimes the therapy changes the care model itself—where treatment happens, how it is financed, what information follows the patient, and which capabilities need to remain connected long after administration.
“Today’s health care system was never designed to enable the types of interventions that revolutionary genomic science and genetic biotechnology enable. We have an opportunity to transform hundreds of millions of lives by realigning the ecosystem, but we need unified, multistakeholder input and collaboration,” said Mimi Lee, MD, PhD, founder and CEO of Opus 132. “If successful, we will achieve predictive, preventive, and precision care for all individuals with improved health outcomes and decreased costs. Why wouldn’t we choose this?”
Standards and accreditation will have to keep pace as care models change. As Phyllis I. Warkentin, MD, FASTCT, chief medical officer of the Foundation for the Accreditation of Cellular Therapy (FACT), explained, “As health care delivery models diversify and expand in response to geographic, socioeconomic, and systemic challenges, [we] recognize the importance of evolving standards and accreditation through consensus of peers and experts in the field of cell and gene therapy. Because the delivery of cell and gene therapies depends on multidisciplinary collaboration, FACT’s standards, accreditation, and educational programs are designed to support emerging care models and promote seamless coordination across the full continuum of the patient journey.”
Readiness, then, is not a designation achieved when the first patient is treated; it is an organizational capability. Leaders do not need to predict every development, but they do need enough flexibility in their people, processes, technology, and financial model to respond when change arrives without sacrificing clinical judgment, patient safety, financial sustainability, or equitable access. Access asks whether a patient can reach a therapy. Readiness asks what happens when they do.
Scientific discovery does not change a patient’s life until it can be delivered. One advanced-therapy episode may connect patient identification, specialist evaluation, payer authorization, manufacturing, logistics, administration, monitoring, data collection, and long-term follow-up. Different teams and organizations may own each step. The patient experiences one journey.
No single profession owns that delivery. Physicians provide clinical leadership alongside nursing, pharmacy, laboratory teams, finance, informatics, manufacturers, administrators, and navigators. Pharmacy is already involved at many points where these therapies can succeed or fail, including medication policy, procurement, preparation, safety, supply chain, finance, informatics, regulatory compliance, and outcomes.
“Pharmacy has always been trusted to find creative and workable solutions to complex medication therapy challenges. No therapies have presented the opportunities and challenges we are seeing with cell, gene, and other next-generation therapeutics,” said Samuel Calabrese, MBA, RPh, CPEL, FASHP, executive vice president and CEO of the American Society of Health-System Pharmacists (ASHP). “It is only through strong collaboration among all stakeholders that these barriers will be overcome, and the ASHP Center for Next-Generation Therapeutics creates that collaborative space across health care to foster the partnerships needed to deliver the solutions our patients deserve.”
Workforce preparation is already underway. ASHP provides gene and cell therapy education covering clinical considerations, logistics, supportive care, and pharmacy leadership, whereas its Center for Next-Generation Therapeutics addresses personalized medicine and other emerging therapies.26,27 As durable interventions change treatment models, medication-
related work may reach further into patient identification, access, complex therapy management, data, and long-term outcomes. Pharmacy’s role cannot end with the medication transaction.
Much of what makes these therapies possible happens out of the patient’s view. As Joe DePinto, MBA, head of cell, gene, and advanced therapies at McKesson, explained, “What enables these therapies to scale isn’t always visible, but it’s essential. Behind every successful treatment is a coordinated system aligning manufacturing, logistics, and care delivery so patients can access the care they need. The systems we build and the challenges we solve today will determine whether we can meet the growing demand that lies ahead.”
Today’s infrastructure may not be tomorrow’s. Manufacturing is becoming more automated and may become more decentralized. Emerging in vivo approaches could also eliminate patient-specific ex vivo processing and some of the logistics around it.15,28,29 Some handoffs may disappear. Others may move. Whatever the model becomes, products, information, decisions, and accountability will still have to connect across organizations.30 The patient should not have to experience the complexity required to make the therapy possible.
Artificial intelligence (AI) may help make increasingly complex information usable without replacing clinical judgment. In a 2025 study involving 1936 test cases across 431 rare diseases, an AI system using electronic health record data outperformed other diagnostic prediction methods. When its predictions were combined with specialist physicians’ assessments, performance improved beyond either approach alone.31 The point is not to replace specialists; it is to help scarce expertise reach further.
AI is also moving closer to the therapies themselves. The Advanced Research Projects Agency for Health’s RAPID project is developing an AI and machine learning platform to design highly modular gene editors.32 AI and digital technologies are also being explored in cell and gene therapy manufacturing, analytics, automation, and process optimization.33 But faster science does not automatically produce cheaper or better medicine.
A 2026 Nature Reviews Drug Discovery review found that despite substantial technical progress in AI-enabled drug discovery, evidence of clinically meaningful impact remains limited.34 Data quality, validation, bias, privacy, transparency, and appropriate human oversight still matter.31,33,34 The value of AI will be measured not by how much human expertise it replaces but by how much more effectively that expertise can be used.
There is reason for optimism. Medicine is gaining tools that can intervene earlier, act more precisely, and, in some cases, alter the course of diseases health care once could only manage. Those advances will also force hard questions about payment, workforce, distribution, long-term outcomes, and who ultimately gets access.
Those challenges should not diminish the optimism of this moment; they should give it direction. Health care has a chance to prepare while many of these models are still taking shape instead of waiting for change to arrive.
The science is advancing. The challenges are substantial. The opportunity to change lives is real. For the patients waiting for what comes next, our responsibility is to be ready when it arrives.




